Shoring Up Osteoporosis Management: A Fresh Start?
- PMID: 39142871
- DOI: 10.3122/jabfm.2024.240060R0
Shoring Up Osteoporosis Management: A Fresh Start?
Abstract
Anabolic bone agents, such as parathyroid hormone receptor agonists (teriparatide and abaloparatide) and sclerostin-inhibiting monoclonal antibody (romosozumab), are superior at preventing clinically significant fractures and/or vertebral fractures in women with and without severe osteoporosis compared with bisphosphonates.
Keywords: Anabolic Bone Agents; Bisphosphonates; Fracture Prevention; Osteoporosis.
Copyright © 2024 by Family Physicians Inquiries Network, Inc.
Conflict of interest statement
Conflict of interest: The authors report no conflict of interest.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical